Biosimilars Market

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

Report Code: PH 7582 Mar, 2020, by marketsandmarkets.com
COVID-19

Click here for an in-depth analysis of the COVID-19 impact on the Biosimilars Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Biosimilars Market

Request Now

[184 Pages Report] The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. This industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness.

Biosimilars Market - By Region 2023

Monoclonal antibodies segment to dominate the biosimilars market in 2019

Based on the product, the biosimilars market industry is segmented into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibody segment accounted for the largest market share in 2019. This is attributed primarily to the rising incidence of cancer and the increasing number of product launches/approvals.

Infliximab segment to dominate the monoclonal antibody industry in 2019

Based on the monoclonal antibody, the biosimilars market industry is segmented into infliximab, rituximab, trastuzumab, adalimumab, and other monoclonal antibodies. The infliximab segment accounted for the largest biosimilars market share in 2019. The growing prevalence of autoimmune diseases drives the market growth.

Biosimilars Market - By Region 2023

Europe was the largest regional market for biosimilars in 2019

The biosimilars market has been analyzed for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, Europe held the largest share of the market, followed by Asia Pacific. The rising incidences of chronic diseases, the increasing geriatric population in this region are the major factors driving the growth of the biosimilars industry in Europe.

Key Market Players

The prominent players operating in biosimilars market include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany),  Boehringer Ingelheim (Germany), Merck KgaA (Germany), Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy's Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

Sandoz (Germany) is one of the leading players in the biosimilars market in 2019. The company boasts of a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the biosimilars market.

Scope of the Report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2018

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Product, Type of Manufacturing, Indication, And Region

Geographies covered

North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), APAC (China, Japan, India, South Korea, Australia, and the RoAPAC), Latin America and Middle East & Africa

Companies covered

Twenty major players were covered, including
Pfizer (US), Sandoz (Germany), Biocon (India), Fresenius Kabi AG (Germany),  Boehringer Ingelheim (Germany), Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy's Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

This research report categorizes the biosimilars market into the following segments and subsegments:

By Product

  • Insulin
  • Recombinant human growth hormone (rhGH)
  • Granulocyte colony-stimulating factor
  • Interferon
  • Erythropoietin
  • Etanercept
  • Monoclonal antibodies
    •  Rituximab
    • Infliximab
    •  Adalimumab
    • Trastuzumab
    • Other Monoclonal Antibodies
  • Follitropin
  • Glucagon
  • Calcitonin
  • Teriparatide
  • Enoxaparin Sodium

By Type of Manufacturing

  • In-House Manufacturing
  • Contract Manufacturing 

By Indication

  • Offsite Treatment
  • Oncology
  • Chronic Disorder
  • Autoimmune Disease
  • Blood Disorders
  • Infectious Disease
  • Other Diseases

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Key Questions Addressed by the Report

  • What are the various biosimilars and their respective market shares in the overall market?
  • Where will these developments shape the industry in the mid-to-long term?
  • What are the recent trends affecting the biosimilars market?
  • Who are the key players in the market, and how intense is the competition?
  • What are the new trends and advancements in the biosimilars market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 20)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
    1.4 YEARS CONSIDERED FOR THE STUDY
    1.5 CURRENCY
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 23)
    2.1 RESEARCH DATA
    2.2 SECONDARY DATA
           2.2.1 SECONDARY SOURCES
    2.3 PRIMARY DATA
           2.3.1 KEY DATA FROM PRIMARY SOURCES
    2.4 MARKET SIZE ESTIMATION
           2.4.1 BOTTOM-UP APPROACH
           2.4.2 GROWTH FORECAST
           2.4.3 TOP-DOWN APPROACH
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 30)

4 PREMIUM INSIGHTS (Page No. - 33)
    4.1 BIOSIMILARS MARKET OVERVIEW
    4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019
    4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET

5 REGULATORY OUTLOOK (Page No. - 36)
    5.1 NORTH AMERICA
           5.1.1 US
           5.1.2 CANADA
    5.2 EUROPE
    5.3 ASIA PACIFIC
           5.3.1 CHINA
           5.3.2 INDIA
           5.3.3 JAPAN
           5.3.4 SOUTH KOREA
           5.3.5 AUSTRALIA
    5.4 REST OF THE WORLD
           5.4.1 BRAZIL
           5.4.2 MEXICO
           5.4.3 ARGENTINA
           5.4.4 SAUDI ARABIA

6 MARKET OVERVIEW (Page No. - 40)
    6.1 INTRODUCTION
    6.2 MARKET DYNAMICS
           6.2.1 DRIVERS
                    6.2.1.1 Increasing demand for biosimilar drugs
                    6.2.1.2 Rising incidence of chronic diseases
           6.2.2 RESTRAINTS
                    6.2.2.1 Complexities in manufacturing
                    6.2.2.2 Resistance from biologic manufacturers
           6.2.3 OPPORTUNITIES
                    6.2.3.1 Emerging markets
                    6.2.3.2 New indications and the patent expiry of biologic products
           6.2.4 CHALLENGES
                    6.2.4.1 Stringent regulatory requirements
           6.2.5 TRENDS
                    6.2.5.1 Collaborations for biosimilar research and clinical trials

7 BIOSIMILARS MARKET, BY PRODUCT (Page No. - 46)
    7.1 INTRODUCTION
    7.2 MONOCLONAL ANTIBODIES
           7.2.1 INFLIXIMAB
                    7.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market
           7.2.2 RITUXIMAB
                    7.2.2.1 Rising incidence of autoimmune diseases and cancer are key drivers for the market growth
           7.2.3 TRASTUZUMAB
                    7.2.3.1 Rising incidences of cancer will drive market growth
           7.2.4 ADALIMUMAB
                    7.2.4.1 Adalimumab will register the highest CAGR in the monoclonal antibodies market
           7.2.5 OTHER MONOCLONAL ANTIBODIES
    7.3 INSULIN
           7.3.1 INCREASING INCIDENCE OF DIABETES WILL SUPPORT MARKET GROWTH
    7.4 GRANULOCYTE COLONY-STIMULATING FACTOR
    7.5 ERYTHROPOIETIN
           7.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
    7.6 RECOMBINANT HUMAN GROWTH HORMONE
           7.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
    7.7 ETANERCEPT
           7.7.1 APAC MARKET FOR ETANERCEPT WILL SHOW THE HIGHEST GROWTH IN THE FORECAST PERIOD
    7.8 FOLLITROPIN
           7.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT WILL DRIVE MARKET GROWTH
    7.9 TERIPARATIDE
           7.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAIN GROWTH DRIVER FOR THIS MARKET
    7.10 INTERFERONS
           7.10.1 MARKET GROWTH IS SUPPORTED BY THE RISING INCIDENCE OF INFECTIOUS DISEASES
    7.11 ENOXAPARIN SODIUM
           7.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
    7.12 GLUCAGON
           7.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
    7.13 CALCITONIN
           7.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS WILL DRIVE THE MARKET

8 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING (Page No. - 61)
    8.1 INTRODUCTION
    8.2 IN-HOUSE MANUFACTURING
           8.2.1 COST-EFFECTIVENESS MAKES IN-HOUSE MANUFACTURING HIGHLY PREFERABLE FOR MOST MARKET PLAYERS
    8.3 CONTRACT MANUFACTURING
           8.3.1 OUTSOURCING PRODUCTION ENABLES COMPANIES TO FOCUS ON CORE COMPETENCY AND PROVIDES COST-BENEFITS

9 BIOSIMILARS MARKET, BY INDICATION (Page No. - 65)
    9.1 INTRODUCTION
    9.2 ONCOLOGY
           9.2.1 RISING BURDEN OF CANCER AND GROWING INCIDENCE HAVE DRIVEN DEMAND FOR BIOSIMILARS
    9.3 CHRONIC DISEASES
           9.3.1 HIGH EFFICACY OF BIOSIMILARS HAS DRIVEN RESEARCH INTO APPLICATIONS IN CHRONIC DISEASE TREATMENT
    9.4 AUTOIMMUNE DISEASES
           9.4.1 GROWING RESEARCH ACTIVITY FOR AUTOIMMUNE DISEASE INDICATIONS WILL FAVOR MARKET GROWTH
    9.5 BLOOD DISORDERS
           9.5.1 POSSIBILITY OF COST-REDUCTIONS IN BLOOD DISORDER TREATMENT WILL SUPPORT MARKET DEMAND FOR BIOSIMILARS
    9.6 GROWTH HORMONE DEFICIENCY
           9.6.1 GROWING CASES OF GH DEFICIENCY DRIVES DEMAND FOR BIOSIMILARS
    9.7 INFECTIOUS DISEASES
           9.7.1 ASIA PACIFIC SHOWS HIGHEST DEMAND FOR BIOSIMILARS IN THIS SEGMENT
    9.8 OTHER INDICATIONS

10 BIOSIMILARS MARKET, BY REGION (Page No. - 76)
     10.1 INTRODUCTION
     10.2 EUROPE
             10.2.1 UK
                        10.2.1.1 The UK holds the largest share of the biosimilars market in Europe
             10.2.2 FRANCE
                        10.2.2.1 Rising geriatric population will drive market growth
             10.2.3 GERMANY
                        10.2.3.1 The presence of a favorable pricing system has supported biosimilar adoption in Germany
             10.2.4 ITALY
                        10.2.4.1 Rising geriatric population in Italy will support market growth
             10.2.5 SPAIN
                        10.2.5.1 R&D investments for the development of innovative drugs is a key growth driver in the Spanish market
             10.2.6 REST OF EUROPE
     10.3 ASIA PACIFIC
             10.3.1 INDIA
                        10.3.1.1 India holds the largest share of the APAC market
             10.3.2 CHINA
                        10.3.2.1 China accounts for the second-largest share of the APAC market
             10.3.3 SOUTH KOREA
                        10.3.3.1 Rising incidences of chronic diseases are expected to drive the market in South Korea
             10.3.4 JAPAN
                        10.3.4.1 Growing geriatric population is expected to drive the market in Japan
             10.3.5 AUSTRALIA
                        10.3.5.1 Increasing number of product launches by companies will drive market growth
             10.3.6 REST OF ASIA PACIFIC
     10.4 NORTH AMERICA
             10.4.1 US
                        10.4.1.1 US will dominate the North American biosimilars market
             10.4.2 CANADA
                        10.4.2.1 Increasing incidences of chronic diseases will drive market growth in Canada
     10.5 LATIN AMERICA
             10.5.1 RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH
     10.6 MIDDLE EAST AND AFRICA
             10.6.1 FAVORABLE HEALTHCARE REFORMS AND INFRASTRUCTURAL DEVELOPMENT WILL FAVOR MARKET GROWTH

11 COMPETITIVE LANDSCAPE (Page No. - 135)
     11.1 OVERVIEW
     11.2 MARKET SHARE ANALYSIS, 2018
     11.3 COMPETITIVE SCENARIO
             11.3.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
             11.3.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
             11.3.3 ACQUISITIONS
             11.3.4 EXPANSIONS
     11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
             11.4.1 VENDOR INCLUSION CRITERIA
             11.4.2 VISIONARY LEADERS
             11.4.3 INNOVATORS
             11.4.4 DYNAMIC DIFFERENTIATORS
             11.4.5 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. - 141)
     12.1 SANDOZ
             12.1.1 BUSINESS OVERVIEW
             12.1.2 PRODUCTS OFFERED
             12.1.3 PRODUCT PIPELINE
             12.1.4 RECENT DEVELOPMENTS
             12.1.5 MNM VIEW
     12.2 PFIZER
             12.2.1 BUSINESS OVERVIEW
             12.2.2 PRODUCTS OFFERED
             12.2.3 PRODUCT PIPELINE
             12.2.4 RECENT DEVELOPMENTS
             12.2.5 MNM VIEW
     12.3 ELI LILLY
             12.3.1 BUSINESS OVERVIEW
             12.3.2 PRODUCTS OFFERED
             12.3.3 MNM VIEW
     12.4 TEVA PHARMACEUTICAL
             12.4.1 BUSINESS OVERVIEW
             12.4.2 PRODUCTS OFFERED
             12.4.3 PRODUCT PIPELINE
             12.4.4 RECENT DEVELOPMENTS
     12.5 CELLTRION
             12.5.1 BUSINESS OVERVIEW
             12.5.2 PRODUCTS OFFERED
             12.5.3 PRODUCT PIPELINE
             12.5.4 RECENT DEVELOPMENTS
     12.6 BIOCON
             12.6.1 BUSINESS OVERVIEW
             12.6.2 PRODUCTS OFFERED
             12.6.3 PRODUCT PIPELINE
             12.6.4 RECENT DEVELOPMENTS
     12.7 AMGEN
             12.7.1 BUSINESS OVERVIEW
             12.7.2 PRODUCTS OFFERED
             12.7.3 PRODUCT PIPELINE
             12.7.4 RECENT DEVELOPMENTS
     12.8 SAMSUNG BIOLOGICS
             12.8.1 BUSINESS OVERVIEW
             12.8.2 PRODUCTS OFFERED
             12.8.3 PRODUCT PIPELINE
             12.8.4 RECENT DEVELOPMENTS
     12.9 MYLAN
             12.9.1 BUSINESS OVERVIEW
             12.9.2 PRODUCTS OFFERED
             12.9.3 RECENT DEVELOPMENTS
     12.10 DR. REDDY’S LABORATORIES
             12.10.1 BUSINESS OVERVIEW
             12.10.2 PRODUCTS OFFERED
             12.10.3 RECENT DEVELOPMENTS
     12.11 STADA ARZNEIMITTEL AG
             12.11.1 BUSINESS OVERVIEW
             12.11.2 PRODUCTS OFFERED
             12.11.3 RECENT DEVELOPMENTS
     12.12 COHERUS BIOSCIENCES
             12.12.1 BUSINESS OVERVIEW
             12.12.2 PRODUCTS OFFERED
             12.12.3 PRODUCT PIPELINE
             12.12.4 RECENT DEVELOPMENTS
     12.13 BIOCAD
             12.13.1 BUSINESS OVERVIEW
             12.13.2 PRODUCTS OFFERED
             12.13.3 PRODUCT PIPELINE
             12.13.4 RECENT DEVELOPMENTS
     12.14 AMEGA BIOTECH
             12.14.1 BUSINESS OVERVIEW
             12.14.2 PRODUCTS OFFERED
     12.15 PROBIOMED
             12.15.1 BUSINESS OVERVIEW
             12.15.2 PRODUCTS OFFERED
     12.16 BOEHRINGER INGELHEIM
             12.16.1 BUSINESS OVERVIEW
             12.16.2 PRODUCTS OFFERED
     12.17 APOTEX
             12.17.1 BUSINESS OVERVIEW
             12.17.2 PRODUCTS OFFERED
             12.17.3 RECENT DEVELOPMENTS
     12.18 FRESENIUS KABI
             12.18.1 BUSINESS OVERVIEW
             12.18.2 PRODUCTS OFFERED
             12.18.3 PRODUCT PIPELINE
             12.18.4 RECENT DEVELOPMENTS
     12.19 GEDEON RICHTER
             12.19.1 BUSINESS OVERVIEW
             12.19.2 PRODUCTS OFFERED
             12.19.3 PRODUCT PIPELINE
             12.19.4 RECENT DEVELOPMENTS
     12.20 MABXIENCE
             12.20.1 BUSINESS OVERVIEW
             12.20.2 PRODUCTS OFFERED
             12.20.3 PRODUCT PIPELINE
             12.20.4 RECENT DEVELOPMENTS

13 APPENDIX (Page No. - 176)
     13.1 INSIGHTS OF INDUSTRY EXPERTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS


LIST OF TABLES (132 Tables)

TABLE 1 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
TABLE 2 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
TABLE 3 STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC
TABLE 4 STATUS OF REGULATORY PATHWAY IN ROW COUNTRIES
TABLE 5 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
TABLE 6 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017–2020)
TABLE 7 BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 8 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 9 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 10 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 13 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 14 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 15 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 16 LIST OF APPROVED BIOSIMILARS FOR G-CSF
TABLE 17 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018–2025 (USD MILLION)
TABLE 18 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 19 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018–2025 (USD MILLION)
TABLE 21 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2018–2025 (USD MILLION)
TABLE 22 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 23 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2018–2025 (USD MILLION)
TABLE 24 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 25 BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2018–2025 (USD MILLION)
TABLE 26 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2018–2025 (USD MILLION)
TABLE 27 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 28 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 29 BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016–2023 (USD BILLION)
TABLE 30 BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2018–2025 (USD MILLION)
TABLE 31 BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 32 BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2017–2019
TABLE 33 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 35 BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2017–2019
TABLE 36 BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 37 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2018–2025 (USD MILLION)
TABLE 39 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 41 BIOSIMILARS MARKET, BY REGION, 2018–2025 (USD BILLION)
TABLE 42 LIST OF BIOSIMILARS APPROVED IN EUROPE
TABLE 43 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 44 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 45 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 46 EUROPE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 47 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 48 LIST OF BIOSIMILARS IN THE UK
TABLE 49 UK: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 50 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 51 UK: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 52 UK: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 53 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 54 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 55 FRANCE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 56 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 57 LIST OF BIOSIMILARS APPROVED IN GERMANY
TABLE 58 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 59 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 60 GERMANY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 61 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 62 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 63 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64 ITALY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 65 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 66 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 67 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 68 SPAIN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 69 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 70 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 71 ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 72 ROE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 73 ROE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 74 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 76 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 77 ASIA PACIFIC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 78 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 79 BIOSIMILARS APPROVED AND MARKETED IN INDIA
TABLE 80 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 81 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 INDIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 83 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 84 BIOSIMILARS APPROVED IN CHINA
TABLE 85 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 86 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87 CHINA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 88 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 89 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
TABLE 90 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 91 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 92 SOUTH KOREA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 93 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 94 LIST OF BIOSIMILARS APPROVED IN JAPAN
TABLE 95 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 96 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 97 JAPAN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 98 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 99 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
TABLE 100 AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 101 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102 AUSTRALIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 103 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 104 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 105 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 106 LIST OF BIOSIMILARS APPROVED IN MALAYSIA
TABLE 107 ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 108 ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 109 ROAPAC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 110 ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 111 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 112 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 113 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 114 NORTH AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 115 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 116 LIST OF BIOSIMILARS APPROVED IN THE US
TABLE 117 US: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 118 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 119 US: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 120 US: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 121 LIST OF BIOSIMILARS APPROVED IN CANADA
TABLE 122 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 123 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 124 CANADA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 125 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 126 LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
TABLE 127 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 128 LATIN AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 129 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 130 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 131 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 132 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)


LIST OF FIGURES (46 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 BIOSIMILARS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION)
FIGURE 7 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2020 VS. 2025 (USD BILLION)
FIGURE 8 BIOSIMILARS MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 9 BIOSIMILARS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION)
FIGURE 10 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
FIGURE 11 INSULIN HELD LARGEST MARKET SHARE IN 2019
FIGURE 12 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 13 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 14 INCREASING GERIATRIC POPULATION, BY REGION, 2019 VS. 2050
FIGURE 15 GLOBAL INCIDENCE OF DIABETES, BY REGION, 2019, 2030, 2045
FIGURE 16 ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET
FIGURE 17 ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2010–2018
FIGURE 18 ARTICLES PUBLISHED ON BIOSIMILARS FOR CHRONIC DISEASES, 2010–2018
FIGURE 19 ARTICLES PUBLISHED ON BIOSIMILARS FOR AUTOIMMUNE DISEASES, 2010–2018
FIGURE 20 ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS, 2010–2018
FIGURE 21 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
FIGURE 22 EUROPE: BIOSIMILARS MARKET SNAPSHOT
FIGURE 23 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE UK, 2010–2018
FIGURE 24 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN FRANCE, 2010–2018
FIGURE 25 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN GERMANY, 2010–2018
FIGURE 26 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN ITALY, 2011–2019
FIGURE 27 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN SPAIN, 2010–2018
FIGURE 28 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
FIGURE 29 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE US, 2010–2018
FIGURE 30 PROJECTED INCREASE IN CANCER INCIDENCE IN CANADA
FIGURE 31 ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN CANADA, 2010–2018
FIGURE 32 KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2017 TO 2020
FIGURE 33 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER 2018
FIGURE 34 MNM DIVE-VENDOR COMPARISON MATRIX: BIOSIMILARS MARKET
FIGURE 35 SANDOZ: COMPANY SNAPSHOT
FIGURE 36 PFIZER: COMPANY SNAPSHOT
FIGURE 37 ELI LILLY: COMPANY SNAPSHOT
FIGURE 38 TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
FIGURE 39 CELLTRION: COMPANY SNAPSHOT
FIGURE 40 BIOCON: COMPANY SNAPSHOT
FIGURE 41 AMGEN: COMPANY SNAPSHOT
FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 43 MYLAN: COMPANY SNAPSHOT
FIGURE 44 DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
FIGURE 45 STADA ARZNEIMITTEL: COMPANY SNAPSHOT
FIGURE 46 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT

The study involved four major activities in estimating the current size of the biosimilars market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Then, both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary sources referred to for research study on the biosimilars market include publications from government sources such as white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations were referred to identify and collect information for this study.

Primary Research

The biosimilars market comprises several stakeholders, such as biosimilars manufacturers and distributors. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Following is a breakdown of the primary respondents:

Biosimilars Market - By Region 2023

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the biosimilars market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry's supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall biosimilars market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the biosimilars industry.

Report Objectives

  • To define, describe, segment, and forecast the biosimilars market by product, type of manufacturing, indication, and region
  • To forecast the size of the market with respect to the main regional segments—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To profile key players and comprehensively analyze their market shares and core competencies2 in terms of market developments and growth strategies
  • To track and analyze competitive developments such as collaborations, regulatory approvals, partnerships, acquisitions, and product launches in the biosimilars market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company's specific needs. The following customization options are available for the medical waste management market report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
  • Company Information: Detailed analysis and profiling of additional market players (Up to 5)
Report Code
PH 7582
Published ON
Mar, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biosimilars Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home